Rahmer Peter, the Chief Corporate Development Officer at Relay Therapeutics, Inc., has sold 753 shares of the company's stock. This transaction was executed to cover his income tax withholding obligations following the vesting of restricted stock units (RSUs) on October 27, 2026. Such sales are common among executives managing their tax liabilities related to stock compensation.

The sale was reported in a recent SEC filing, which indicates that Peter had no discretion over the timing of the sale, as it was conducted according to the company's policies regarding RSU vesting. Following this transaction, he retains ownership of 222,904 shares, which include 3,051 shares underlying the RSUs.

About Relay Therapeutics

Relay Therapeutics, Inc. is a biotechnology company focused on advancing the field of drug discovery. The company is incorporated in Delaware and operates primarily in the biological products sector, specifically under the SIC code for Biological Products (No Diagnostic Substances) [2836]. Relay Therapeutics is headquartered in Cambridge, Massachusetts, and is publicly traded under the ticker symbol RLAY.

Details from the Filing

The SEC filing, accession number 0001193125-26-441713, reveals that the transaction took place on October 28, 2026, with a price per share of $18.62. The filing notes: "Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 3,051 shares of restricted stock units (RSUs) on October 27, 2026." This highlights the financial management strategies employed by executives in the biotech industry.

Impact on Stakeholders

This transaction may affect various stakeholders, including investors and analysts monitoring Relay Therapeutics' stock performance. Such sales can influence perceptions of insider confidence in the company's future prospects, especially in the competitive biotech landscape.

What's Next?

The filing does not say what happens next.